Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

• DOI: 10.1016/j.jaad.2023.04.063
• Publication Date: 2023-05-12T15:23:22Z
• Authors: Bruce Strober; Carle Paul; Andrew Blauvelt; Diamant Thaçi; Luis Puig; Mark Lebwohl; Katy White; Veerle Vanvoorden; Delphine Deherder; Natalie Nunez Gomez; Kilian Eyerich
• Keywords: Treatment Outcome; Double-Blind Method; 610; Humans; COVID-19; Antibodies, Monoclonal; Psoriasis; Pandemics; Severity of Illness Index; 3. Good health

BackgroundBimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab more efficacious than secukinumab over 1 year in the treatment of psoriasis.ObjectiveEvaluate safety and efficacy bimekizumab through 2 years patients with moderate to severe plaque psoriasis.MethodsThe BE RADIANT phase 3b randomized controlled trial consisted 48-week double-blinded period, where received (320 mg every 4 or 8 weeks) (300 weekly Week 4, then weeks), an open-label extension (OLE). From 48, all OLE.ResultsAt achieved complete skin clearance (PASI 100; modified non-responder imputation) (74.8% vs 52.8%). PASI 100 responses were maintained 96 continuous (70.8%); who switched from had increased rates at (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, urinary tract infection. Safety data consistent known profile bimekizumab.LimitationsLimited racial diversity; overlap COVID-19 pandemic.ConclusionsHigh 48 weeks sustained 96; similar by 96. psoriasis. Evaluate OLE. At bimekizumab. Limited pandemic. High